Artelo Biosciences, Inc. has announced positive interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) for ART27.13, a cannabinoid receptor agonist designed to treat cancer anorexia-cachexia syndrome (CACS). This syndrome, which affects up to 80% of cancer patients, leads to significant weight loss and muscle wasting, contributing to poor patient outcomes. The interim data indicates a compelling efficacy signal for ART27.13, particularly in weight gain and lean body mass, which may accelerate the drug’s path to market.
In the trial, patients receiving the highest dose of ART27.13 experienced a mean weight gain of 6.38% over 12 weeks, contrasting sharply with a weight loss of 5.42% in the placebo group. Additionally, improvements were observed in both lean body mass and activity levels, critical factors for regulatory approval. The safety profile remains consistent with earlier studies, reinforcing the drug’s tolerability. Artelo’s strategic focus on partnering with pharmaceutical companies familiar with ART27.13 aims to expedite development and maximize shareholder value. The findings underscore the potential of ART27.13 to address a significant unmet medical need in oncology, positioning Artelo as a key player in the therapeutic landscape for cancer-related cachexia.
